Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.40 +4.5%	$20.69	$10.21 ▼ $25.67	$4.20B	0.47	3.70 million shs	4.47 million shs
AKRO Akero Therapeutics	$56.28 +2.3%	$47.25	$21.02 ▼ $58.40	$4.39B	-0.16	1.03 million shs	2.25 million shs
CRMD CorMedix	$14.96 -0.1%	$11.96	$3.61 ▼ $17.43	$1.02B	1.62	1.27 million shs	1.30 million shs
PCVX Vaxcyte	$32.88 -0.6%	$33.22	$27.66 ▼ $121.06	$4.27B	1.2	1.45 million shs	1.60 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+4.55%	+1.49%	-7.49%	-9.18%	+69.74%
AKRO Akero Therapeutics	+2.25%	+2.51%	+22.35%	+31.74%	+145.44%
CRMD CorMedix	-0.07%	+10.16%	+19.39%	+121.96%	+260.48%
PCVX Vaxcyte	-0.63%	-1.56%	+3.62%	-52.66%	-56.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.7075 of 5 stars	3.7	1.0	0.0	2.0	2.5	3.1
AKRO Akero Therapeutics	3.653 of 5 stars	3.5	1.0	4.7	1.8	1.7	0.0
CRMD CorMedix	1.0052 of 5 stars	2.6	1.0	0.0	2.0	0.0	0.6
PCVX Vaxcyte	3.0596 of 5 stars	4.6	2.0	0.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	50.36% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	46.59% Upside
CRMD CorMedix	3.17	Buy	$16.67	11.41% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	315.15% Upside

Current Analyst Ratings Breakdown

Latest CRMD, AKRO, PCVX, and ADMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00
5/6/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/22/2025	PCVX Vaxcyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
4/9/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/8/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.30	$0.57 per share	32.52	$1.48 per share	12.43
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
CRMD CorMedix	$43.47M	23.34	N/A	N/A	$1.40 per share	10.69
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.65	26.67	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
CRMD CorMedix	-$17.93M	$0.22	68.00	15.91	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest CRMD, AKRO, PCVX, and ADMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AKRO Akero Therapeutics	0.03	16.80	16.80
CRMD CorMedix	N/A	4.21	3.99
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
CRMD CorMedix	34.18%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AKRO Akero Therapeutics	7.07%
CRMD CorMedix	5.30%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

CRMD, AKRO, PCVX, and ADMA Headlines

Recent News About These Companies

GAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

June 21, 2025 | marketbeat.com

Assenagon Asset Management S.A. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 14, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Rhumbline Advisers

June 12, 2025 | marketbeat.com

Brokers Offer Predictions for Vaxcyte FY2026 Earnings

June 11, 2025 | marketbeat.com

Vaxcyte: Sentiment Is Pushing The Shares Down

June 10, 2025 | seekingalpha.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

103,683 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Universal Beteiligungs und Servicegesellschaft mbH

June 1, 2025 | marketbeat.com

California State Teachers Retirement System Has $8.60 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 1, 2025 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Stock Price Up 5.7% - Should You Buy?

May 30, 2025 | marketbeat.com

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

May 27, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

May 27, 2025 | marketbeat.com

Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?

May 9, 2025 | insidermonkey.com

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | globenewswire.com

Vaxcyte appoints new independent director

May 3, 2025 | uk.investing.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

May 1, 2025 | tipranks.com

Vaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine Development

May 1, 2025 | quiverquant.comQ

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025 | globenewswire.com

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

April 29, 2025 | insidermonkey.com

Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options

April 23, 2025 | nasdaq.com

Cantor Fitzgerald Initiates Coverage of Vaxcyte (PCVX) with Overweight Recommendation

April 23, 2025 | msn.com

TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, AKRO, PCVX, and ADMA Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.40 +0.80 (+4.55%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.36 -0.04 (-0.19%)

As of 04:36 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$56.28 +1.24 (+2.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$56.50 +0.22 (+0.39%)

As of 04:21 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CorMedix NASDAQ:CRMD

$14.96 -0.01 (-0.07%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$13.36 -1.60 (-10.66%)

As of 04:42 AM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Vaxcyte NASDAQ:PCVX

$32.88 -0.21 (-0.63%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$32.98 +0.10 (+0.29%)

As of 04:04 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time